Mylan N.V. (NASDAQ:MYL)‘s stock had its “hold” rating reiterated by stock analysts at Cowen and Company in a research report issued to clients and investors on Thursday. They presently have a $43.00 price objective on the stock. Cowen and Company’s price target would indicate a potential upside of 30.62% from the stock’s current price.

A number of other brokerages have also commented on MYL. Royal Bank Of Canada decreased their price objective on Mylan N.V. from $39.00 to $36.00 and set a “sector perform” rating on the stock in a report on Thursday, May 11th. Wells Fargo & Company reaffirmed a “market perform” rating and issued a $40.00 price objective on shares of Mylan N.V. in a report on Wednesday, May 31st. Zacks Investment Research raised Mylan N.V. from a “sell” rating to a “hold” rating in a report on Thursday, May 25th. BidaskClub raised Mylan N.V. from a “sell” rating to a “hold” rating in a report on Thursday, June 22nd. Finally, Barclays PLC raised Mylan N.V. from an “equal weight” rating to an “overweight” rating and upped their price objective for the company from $47.00 to $50.00 in a report on Monday, May 22nd. Two analysts have rated the stock with a sell rating, ten have issued a hold rating, twelve have assigned a buy rating and two have issued a strong buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $50.92.

Shares of Mylan N.V. (MYL) traded down 5.13% on Thursday, reaching $32.92. The company had a trading volume of 12,669,007 shares. Mylan N.V. has a 52-week low of $32.77 and a 52-week high of $50.40. The firm has a market capitalization of $17.64 billion, a price-to-earnings ratio of 32.89 and a beta of 1.27. The company’s 50-day moving average price is $38.42 and its 200-day moving average price is $39.28.

Mylan N.V. (NASDAQ:MYL) last issued its quarterly earnings data on Wednesday, May 10th. The company reported $0.93 EPS for the quarter, beating analysts’ consensus estimates of $0.92 by $0.01. Mylan N.V. had a return on equity of 23.69% and a net margin of 4.59%. The firm had revenue of $2.72 billion for the quarter, compared to analyst estimates of $2.81 billion. During the same period in the prior year, the firm posted $0.76 EPS. The company’s revenue for the quarter was up 24.1% on a year-over-year basis. On average, analysts predict that Mylan N.V. will post $5.16 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “Mylan N.V. (NASDAQ:MYL) Rating Reiterated by Cowen and Company” was first reported by Daily Political and is owned by of Daily Political. If you are reading this story on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark law. The correct version of this story can be read at https://www.dailypolitical.com/2017/08/06/mylan-n-v-nasdaqmyl-rating-reiterated-by-cowen-and-company.html.

In related news, insider Anthony Mauro sold 10,000 shares of the company’s stock in a transaction on Friday, June 9th. The stock was sold at an average price of $40.00, for a total transaction of $400,000.00. Following the completion of the sale, the insider now directly owns 140,653 shares in the company, valued at approximately $5,626,120. The sale was disclosed in a filing with the SEC, which is available through this link. Also, President Rajiv Malik sold 25,000 shares of the company’s stock in a transaction on Friday, June 9th. The stock was sold at an average price of $40.00, for a total value of $1,000,000.00. Following the sale, the president now owns 799,855 shares of the company’s stock, valued at $31,994,200. The disclosure for this sale can be found here. 0.69% of the stock is owned by corporate insiders.

Several hedge funds have recently made changes to their positions in MYL. Quadrature Capital Ltd acquired a new stake in shares of Mylan N.V. during the fourth quarter valued at $707,000. Chevy Chase Trust Holdings Inc. increased its stake in shares of Mylan N.V. by 3.1% in the first quarter. Chevy Chase Trust Holdings Inc. now owns 397,825 shares of the company’s stock valued at $15,511,000 after buying an additional 11,931 shares in the last quarter. New England Research & Management Inc. increased its stake in shares of Mylan N.V. by 3.0% in the first quarter. New England Research & Management Inc. now owns 8,450 shares of the company’s stock valued at $329,000 after buying an additional 250 shares in the last quarter. Raymond James Trust N.A. increased its stake in shares of Mylan N.V. by 33.8% in the first quarter. Raymond James Trust N.A. now owns 10,215 shares of the company’s stock valued at $398,000 after buying an additional 2,583 shares in the last quarter. Finally, Legacy Private Trust Co. acquired a new stake in shares of Mylan N.V. during the first quarter valued at $202,000. Institutional investors and hedge funds own 69.86% of the company’s stock.

About Mylan N.V.

Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.

Analyst Recommendations for Mylan N.V. (NASDAQ:MYL)

Receive News & Ratings for Mylan N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan N.V. and related companies with MarketBeat.com's FREE daily email newsletter.